In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down with Bob Vigersky, MD, Chief Medical Officer of Medtronic Diabetes, to discuss major developments in diabetes technology, regulatory approvals, and the company's future direction. Vigersky begins by highlighting Medtronic's newest CGM technologies. The Instinct sensor, developed in collaboration with Abbott, is a 15-day, factory-calibrated sensor that represents a significant step forward in wear duration and convenience. Alongside it is the Simplera Sync sensor, a fully disposable 7-day option that integrates seamlessly with Medtronic's MiniMed 780G automated insulin delivery system. Together with the Guardian 4 sensor, these options provide patients and providers with unprecedented flexibility and choice, enabling customization based on lifestyle needs, preferences, and infusion set change schedules.